Stockreport

Chi-Med Announces Surufatinib Granted U.S. FDA Fast Track Designations for the Treatment of Both Pancreatic and Non-Pancreatic Neuroendocrine Tumors

HUTCHMED (China) Limited - American Depositary Shares  (HCM) 
NASDAQ:AMEX Investor Relations: chi-med.com/investors/information-for-shareholders
PDF LONDON, April 17, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM) today announces that the U.S. Food and Drug Administration (“ [Read more]